Search
Displaying 1–10 of 526 for “Retinitis pigmentosa”
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
-
Disease
Often diagnosed in childhood or adolescence, retinitis pigmentosa (RP) is an inherited retinal disease causing progressive loss of night and peripheral vision. The condition often leads to legal and sometimes complete blindness.
-
Life as a Teen with Retinitis Pigmentosa
Beacon StoriesAt a mere 15 years old, Ava Ruggiero’s world shifted when she received a diagnosis of retinitis pigmentosa. As Ava continues to find balance as a student and athlete, she discusses the challenges of navigating her diagnosis alongside her parents, Joseph and Stephanie.
-
Dr. Eliot Berson, Pioneer in Vitamin A Therapy for Retinitis Pigmentosa, Passes Away
Research NewsDr. Berson dedicated himself to clinical care and vision-saving research for people with inherited retinal diseases for five decades.
-
Research News
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
Research News
The treatment focuses on the P23H mutation in the RHO gene, which is the most prevalent variant causing adRP in the US and affects approximately 2,500 people.
-
Stem-Cell Therapy for Retinitis Pigmentosa Safe Thus Far in Early Human Study
Research NewsThe trial is one of the first-ever for a stem-cell-derived therapy for RP.
-
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Is Acupuncture a Beneficial Treatment for Retinitis Pigmentosa?
Research NewsAcupuncture definitely has potential benefits, and the breadth of those is being aggressively explored.
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Research NewsThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
